222 related articles for article (PubMed ID: 32127519)
21. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
[TBL] [Abstract][Full Text] [Related]
22. The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party.
Rubio MT; Savani BN; Labopin M; Polge E; Niederwieser D; Ganser A; Schwerdtfeger R; Ehninger G; Finke J; Renate A; Craddock C; Kröger N; Hallek M; Jindra P; Mohty M; Nagler A
J Hematol Oncol; 2016 Aug; 9(1):65. PubMed ID: 27488518
[TBL] [Abstract][Full Text] [Related]
23. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
Nagler A; Rocha V; Labopin M; Unal A; Ben Othman T; Campos A; Volin L; Poire X; Aljurf M; Masszi T; Socie G; Sengelov H; Michallet M; Passweg J; Veelken H; Yakoub-Agha I; Shimoni A; Mohty M
J Clin Oncol; 2013 Oct; 31(28):3549-56. PubMed ID: 23980086
[TBL] [Abstract][Full Text] [Related]
24. Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT.
Brands-Nijenhuis AV; Labopin M; Schouten HC; Volin L; Socié G; Cornelissen JJ; Huynh A; Ljungman P; Malard F; Esteve J; Nagler A; Mohty M
Haematologica; 2016 Feb; 101(2):248-55. PubMed ID: 26589909
[TBL] [Abstract][Full Text] [Related]
25. Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning-a matched pair analysis.
Doppelhammer M; Fraccaroli A; Prevalsek D; Bücklein V; Häbe S; Schulz C; Hubmann M; Hausmann A; Claus R; Rank A; Schmid C; Tischer J
Ann Hematol; 2019 Mar; 98(3):753-762. PubMed ID: 30617644
[TBL] [Abstract][Full Text] [Related]
26. Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study.
Sengsayadeth S; Gatwood KS; Boumendil A; Labopin M; Finke J; Ganser A; Stelljes M; Ehninger G; Beelen D; Niederwieser D; Blaise D; Dreger P; Mufti G; Chevallier P; Mailhol A; Gilleece MH; Gorin N; Esteve J; Ciceri F; Baron F; Schmid C; Giebel S; Mohty M; Savani BN; Nagler A
Blood Adv; 2018 Aug; 2(16):2127-2135. PubMed ID: 30143527
[TBL] [Abstract][Full Text] [Related]
27. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.
Granfeldt Østgård LS; Medeiros BC; Sengeløv H; Nørgaard M; Andersen MK; Dufva IH; Friis LS; Kjeldsen E; Marcher CW; Preiss B; Severinsen M; Nørgaard JM
J Clin Oncol; 2015 Nov; 33(31):3641-9. PubMed ID: 26304885
[TBL] [Abstract][Full Text] [Related]
28. Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission.
Lv M; Wang Y; Chang YJ; Zhang XH; Xu LP; Jiang Q; Jiang H; Lu J; Chen H; Han W; Wang FR; Wang JZ; Chen Y; Yan CH; Zhang YY; Sun YQ; Mo XD; Zhu HH; Jia JS; Zhao T; Wang J; Liu KY; Huang XJ
Clin Cancer Res; 2019 Mar; 25(6):1737-1748. PubMed ID: 30478089
[TBL] [Abstract][Full Text] [Related]
29. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party.
Rubio MT; D'Aveni-Piney M; Labopin M; Hamladji RM; Sanz MA; Blaise D; Ozdogu H; Daguindeau E; Richard C; Santarone S; Irrera G; Yakoub-Agha I; Yeshurun M; Diez-Martin JL; Mohty M; Savani BN; Nagler A
J Hematol Oncol; 2017 Jan; 10(1):31. PubMed ID: 28118857
[TBL] [Abstract][Full Text] [Related]
30. Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT).
Maffini E; Labopin M; Beelen DW; Kroeger N; Arat M; Wilson KMO; Bay JO; Ganser A; Martin H; Passweg J; Kottaridis PD; Yakoub-Agha I; Porras RP; Wagner EM; Esteve J; Lanza F; Nagler A; Mohty M
Bone Marrow Transplant; 2022 Oct; 57(10):1556-1563. PubMed ID: 35835997
[TBL] [Abstract][Full Text] [Related]
31. Impact of early remission by induction therapy on allogeneic stem cell transplantation for acute myeloid leukemia with an intermediate-risk karyotype in first complete remission.
Hemmati PG; Terwey TH; Na IK; le Coutre P; Jehn CF; Vuong LG; Dörken B; Arnold R
Eur J Haematol; 2015 May; 94(5):431-8. PubMed ID: 25220715
[TBL] [Abstract][Full Text] [Related]
32. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
[TBL] [Abstract][Full Text] [Related]
33. Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study.
Ruggeri A; Battipaglia G; Labopin M; Ehninger G; Beelen D; Tischer J; Ganser A; Schwerdtfeger R; Glass B; Finke J; Michallet M; Stelljes M; Jindra P; Arnold R; Kröger N; Mohty M; Nagler A
J Hematol Oncol; 2016 Sep; 9(1):89. PubMed ID: 27639553
[TBL] [Abstract][Full Text] [Related]
34. Autologous stem cell transplantation (ASCT) for acute myeloid leukemia in patients in first complete remission after one versus two induction courses: A study from the ALWP of the EBMT.
Nagler A; Galimard JE; Labopin M; Blaise D; Arcese W; Trisolini SM; Wu D; Pigneux A; Van Gorkom G; Rubio MT; Gedde-Dahl T; Huynh A; Lanza F; Gorin NC; Mohty M
Cancer Med; 2023 Jan; 12(2):1482-1491. PubMed ID: 35891608
[TBL] [Abstract][Full Text] [Related]
35. Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia.
Nagler A; Peczynski C; Dholaria B; Labopin M; Valerius T; Dreger P; Kröger N; Reinhardt HC; Finke J; Franke GN; Ciceri F; Verbeek M; Blau IW; Bornhäuser M; Spyridonidis A; Bug G; Bazarbachi A; Schmid C; Yakoub-Agha I; Savani BN; Mohty M
Bone Marrow Transplant; 2022 Jul; 57(7):1116-1123. PubMed ID: 35501565
[TBL] [Abstract][Full Text] [Related]
36. Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT.
Ringdén O; Labopin M; Schmid C; Sadeghi B; Polge E; Tischer J; Ganser A; Michallet M; Kanz L; Schwerdtfeger R; Nagler A; Mohty M;
Br J Haematol; 2017 Feb; 176(3):431-439. PubMed ID: 27879990
[TBL] [Abstract][Full Text] [Related]
37. Role of alternative donor allogeneic hematopoietic stem cell transplantation in patients with intermediate- or poor-risk acute myeloid leukemia in first complete remission.
Yano S; Yokoyama H; Yanada M; Mori J; Aoki J; Ohashi K; Kanomori H; Ozawa Y; Sawa M; Nakamae H; Eto T; Ohta S; Tanaka J; Ichinohe T; Atsuta Y; Takami A
Bone Marrow Transplant; 2019 Dec; 54(12):2004-2012. PubMed ID: 31152148
[TBL] [Abstract][Full Text] [Related]
38. Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC.
Chevallier P; Labopin M; Socie G; Rubio MT; Blaise D; Vigouroux S; Huynh A; Michallet M; Bay JO; Maury S; Yakoub-Agha I; Fegueux N; Deconinck E; Contentin N; Maillard N; Bulabois CE; Francois S; Oumedaly R; Raus N; Mohty M
Eur J Haematol; 2015 May; 94(5):449-55. PubMed ID: 25238651
[TBL] [Abstract][Full Text] [Related]
39. Transplant outcomes for patients with therapy-related acute myeloid leukemia with prior lymphoid malignancy: an ALWP of EBMT study.
Gatwood KS; Labopin M; Savani BN; Finke J; Socie G; Beelen D; Yakoub-Agha I; Chevallier P; Ganser A; Blaise D; Milpied N; Bruno L; Mailhol A; Mohty M; Nagler A
Bone Marrow Transplant; 2020 Jan; 55(1):224-232. PubMed ID: 31527819
[TBL] [Abstract][Full Text] [Related]
40. High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission.
Schmid C; Schleuning M; Hentrich M; Markl GE; Gerbitz A; Tischer J; Ledderose G; Oruzio D; Hiddemann W; Kolb HJ
Bone Marrow Transplant; 2008 Apr; 41(8):721-7. PubMed ID: 18176613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]